Trial intelligence / Profile preview

Phase 3b ocular side effect management study of depatuxizumab mafodotin in EGFR-amplified glioblastoma

2017-003171-64Phase 3Completed

Sponsor: AbbVie Inc.
Start: Mar 2018
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of depatuxizumab mafodotin in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by AbbVie Inc. Started Mar 2018; status: completed.

Drugs

depatuxizumab mafodotin

Conditions

glioblastoma (GBM)Gliosarcoma (GS)

Beyond the preview

Go deeper on 2017-003171-64.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-003171-64.